Yuyu Pharma Files First Corporate Governance Report: Weak Shareholder Communication & Dividend Predictability, but Efforts Include e-Voting & Share Buyback
Yuyu Pharma has filed its first mandatory corporate governance report for FY2025, transparently disclosing non-compliance with many of the 15 key indicators.
Key non-compliances include failure to send shareholder meeting notice 4 weeks prior (only 17 days for the 86th AGM) and dividend predictability issues (record date before dividend decision).
Formal dividend policy, CEO succession plan, board operating rules, individual evaluation of outside directors, and compensation committee are absent, requiring systematic improvement.
The board consists of 2 inside and 3 outside directors (60%), but the chairman is an inside director (CEO), and the only board committee is the audit committee.
The audit committee is composed entirely of 3 outside directors, including an accounting/finance expert (Lee Seung-woo), and operates an internal audit department (Legal & Audit Team).
Positive steps include adoption of electronic voting (last 3 years), share buyback of 435,211 common shares (~KRW 2 billion) in Apr-Jul 2025, and articles amendment to set the record date after dividend decision from FY2026 onward.
For FY2025, consolidated revenue was KRW 140.9 billion, operating profit KRW 11.0 billion, net income KRW 9.1 billion, with revenue up but operating profit slightly down YoY.
Majority shareholder stake is 33.23%, and convertible bonds (30th and 31st series) with KRW 11.81 billion outstanding can convert into 2,535,145 shares, posing potential dilution risk.
Dividend for FY2025: common shares KRW 115 per share (2.5% yield), preferred shares KRW 125 per share (2.4% and 1.1% yield).
[AI Comprehensive Analysis]While transparent disclosure of governance gaps is positive, the lack of fundamental shareholder protection mechanisms (dividend policy, CEO succession, board independence) requires urgent improvement and may negatively impact short-term stock performance.